US healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has announced finncial results for third-quarter 2023.
The firm’s reported sales in the quarter grew by 7% to $21.35 billion, above analysts' estimates of $21.04 billion.
Excluding items, J&J reported a profit of $2.66 per share, above estimates of $2.52 and up 19% on the same period last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze